350 related articles for article (PubMed ID: 37261583)
1. Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Dote S; Shiwaku E; Kohno E; Fujii R; Mashimo K; Morimoto N; Yoshino M; Odaira N; Ikesue H; Hirabatake M; Takahashi K; Takahashi M; Takagi M; Nishiuma S; Ito K; Shimato A; Itakura S; Takahashi Y; Negoro Y; Shigemori M; Watanabe H; Hayasaka D; Nakao M; Tasaka M; Goto E; Kataoka N; Yokomizo A; Kobayashi A; Nakata Y; Miyake M; Hayashi Y; Yamamoto Y; Hirata T; Azuma K; Makihara K; Fukui R; Tokutome A; Yagisawa K; Honda S; Meguro Y; Suzuki S; Yamaguchi D; Miyata H; Kobayashi Y;
Int J Clin Oncol; 2023 Aug; 28(8):1054-1062. PubMed ID: 37261583
[TBL] [Abstract][Full Text] [Related]
2. Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor.
Yamazaki K; Yuki S; Oki E; Sano F; Makishima M; Aoki K; Hamano T; Yamanaka T
Clin Colorectal Cancer; 2021 Sep; 20(3):e173-e184. PubMed ID: 33875364
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Yamazaki K; Nagase M; Tamagawa H; Ueda S; Tamura T; Murata K; Eguchi Nakajima T; Baba E; Tsuda M; Moriwaki T; Esaki T; Tsuji Y; Muro K; Taira K; Denda T; Funai S; Shinozaki K; Yamashita H; Sugimoto N; Okuno T; Nishina T; Umeki M; Kurimoto T; Takayama T; Tsuji A; Yoshida M; Hosokawa A; Shibata Y; Suyama K; Okabe M; Suzuki K; Seki N; Kawakami K; Sato M; Fujikawa K; Hirashima T; Shimura T; Taku K; Otsuji T; Tamura F; Shinozaki E; Nakashima K; Hara H; Tsushima T; Ando M; Morita S; Boku N; Hyodo I
Ann Oncol; 2016 Aug; 27(8):1539-46. PubMed ID: 27177863
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
5. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Souglakos J; Ziras N; Kakolyris S; Boukovinas I; Kentepozidis N; Makrantonakis P; Xynogalos S; Christophyllakis Ch; Kouroussis Ch; Vamvakas L; Georgoulias V; Polyzos A
Br J Cancer; 2012 Jan; 106(3):453-9. PubMed ID: 22240792
[TBL] [Abstract][Full Text] [Related]
6. Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.
Suzuki T; Shinozaki E; Osumi H; Nakayama I; Ota Y; Ichimura T; Ogura M; Wakatsuki T; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
Cancer Chemother Pharmacol; 2019 Aug; 84(2):307-313. PubMed ID: 31065729
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Jo H; Lee MS; Lee YP; Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
Clin Oncol (R Coll Radiol); 2022 Aug; 34(8):e323-e328. PubMed ID: 35248464
[TBL] [Abstract][Full Text] [Related]
8. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
[TBL] [Abstract][Full Text] [Related]
9. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
10. [FOLFIRI plus RAM Therapy in Later Line of Unresectable Colorectal Cancer].
Naito A; Imasato M; Iwamoto K; Takeda M; Hyuga S; Ohashi T; Nakahara Y; Furukawa K; Moon J; Asaoka T; Mizushima T
Gan To Kagaku Ryoho; 2023 Jan; 50(1):113-115. PubMed ID: 36760004
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study.
Lim AR; Kim JH; Hyun MH; Kim YH; Lee S
Support Care Cancer; 2022 Oct; 30(10):8129-8137. PubMed ID: 35779133
[TBL] [Abstract][Full Text] [Related]
12. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
13. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
[TBL] [Abstract][Full Text] [Related]
14. Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer.
Kimura M; Usami E; Teramachi H; Yoshimura T
Anticancer Res; 2021 Jun; 41(6):3091-3097. PubMed ID: 34083302
[TBL] [Abstract][Full Text] [Related]
15. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
[TBL] [Abstract][Full Text] [Related]
16. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
17. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Kamiimabeppu D; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K
Cancer Med; 2021 Jan; 10(2):615-625. PubMed ID: 33347731
[TBL] [Abstract][Full Text] [Related]
18. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
Holch JW; Held S; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; von Einem JC; Michl M; Heinemann V
Ann Oncol; 2020 Jan; 31(1):72-78. PubMed ID: 31912799
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
